Notícias

Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the...

Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad

(Updates with Novo Nordisk's response in the fourth paragraph.) Novo Nordisk's (NVO) Ozempic and

The findings could broaden the long-term opportunity for obesity and diabetes treatments.

The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.

Late-stage trial data strengthens Lilly's obesity drug pipeline.

Retatrutide helped patients lose up to 28.3% of body weight over 80 weeks.

Eli Lilly and Company (NYSE:LLY), featuring a net income margin of 34.99% and upside potential of 20.64%, secures a spot on our list of the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $20.64 billion for the recently completed fiscal year (FY25). That earnings strength was […]

Novo Nordisk presented new Phase 3 ESSENCE data on semaglutide’s liver safety and efficacy at EASL 2026. The update includes the first dedicated results in menopausal women and Japanese patients with MASH. Findings suggest a consistent hepatic safety profile across these historically underrepresented groups. Novo Nordisk (CPSE:NOVO B) is drawing fresh attention with these MASH data at a time when its share price stands at DKK288.4. The stock is up 11.8% over the past 30 days but remains...

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

European equities traded in the US as American depositary receipts were tracking marginally lower la

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

Eli Lilly’s investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.

Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.

By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's

Demand for weight loss drugs may fuel growth for more than one player.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue ... Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U. Prices for the lowest doses of both Novo's oral Wegovy and Lilly's Foundayo tend to be lower than for their injected obesity ‌medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions.

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Novo Nordisk-linked pharmaceutical strength helped Denmark post a fourth straight quarter of economic expansion.

Earlier in May 2026, Novo Nordisk presented new sub-analyses from its OASIS 4 and STEP UP phase 3 trials at the European Congress on Obesity, showing strong weight-loss efficacy, improved physical function and favourable body composition effects for both oral and injectable Wegovy across diverse adult and female patient groups. The company also reported that Wegovy’s oral pill compared favourably with rival orforglipron on weight loss, tolerability and patient preference, reinforcing...

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.

Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.

(Updates with Novo Nordisk's response in the fourth and fifth paragraphs.) The US Supreme Court o

Novo Nordisk (CPSE:NOVO B) is transferring its clinical-stage Parkinson's cell therapy program, including global rights, to Cellular Intelligence. As part of the deal, Novo Nordisk will take an equity stake in Cellular Intelligence and remain eligible for milestones and royalties linked to the therapy. The program holds fast track designation for Parkinson's disease and aims to use AI-supported manufacturing and clinical optimization to accelerate development timelines. Novo Nordisk, best...